WO2002000879A3 - Methods for producing modified glycoproteins - Google Patents
Methods for producing modified glycoproteins Download PDFInfo
- Publication number
- WO2002000879A3 WO2002000879A3 PCT/US2001/020553 US0120553W WO0200879A3 WO 2002000879 A3 WO2002000879 A3 WO 2002000879A3 US 0120553 W US0120553 W US 0120553W WO 0200879 A3 WO0200879 A3 WO 0200879A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- glycoproteins
- human
- produce
- glycans
- fungi
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2477—Hemicellulases not provided in a preceding group
- C12N9/2488—Mannanases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01113—Mannosyl-oligosaccharide 1,2-alpha-mannosidase (3.2.1.113), i.e. alpha-1,2-mannosidase
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/04—Fusion polypeptide containing a localisation/targetting motif containing an ER retention signal such as a C-terminal HDEL motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/05—Fusion polypeptide containing a localisation/targetting motif containing a GOLGI retention signal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
Abstract
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MXPA03000105A MXPA03000105A (en) | 2000-06-28 | 2001-06-27 | Methods for producing modified glycoproteins. |
KR1020027017911A KR100787073B1 (en) | 2000-06-28 | 2001-06-27 | Methods for producing modified glycoproteins |
AU7684201A AU7684201A (en) | 2000-06-28 | 2001-06-27 | Methods for producing modified glycoproteins |
NZ523476A NZ523476A (en) | 2000-06-28 | 2001-06-27 | Methods for humanizing glycosylation of recombinant glycoproteins expressed in lower eukaryotes |
AT01954606T ATE309385T1 (en) | 2000-06-28 | 2001-06-27 | METHOD FOR PRODUCING MODIFIED GLYCOPROTEINS |
AU2001276842A AU2001276842B2 (en) | 2000-06-28 | 2001-06-27 | Methods for producing modified glycoproteins |
JP2002506194A JP2004501642A (en) | 2000-06-28 | 2001-06-27 | Methods for producing modified glycoproteins |
CA002412701A CA2412701A1 (en) | 2000-06-28 | 2001-06-27 | Methods for producing modified glycoproteins |
DK04025648T DK1522590T3 (en) | 2000-06-28 | 2001-06-27 | Process for Preparation of Modified Glycoproteins |
EP01954606A EP1297172B1 (en) | 2000-06-28 | 2001-06-27 | Methods for producing modified glycoproteins |
DE60114830T DE60114830T2 (en) | 2000-06-28 | 2001-06-27 | PROCESS FOR PRODUCING MODIFIED GLYCOPROTEINS |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21435800P | 2000-06-28 | 2000-06-28 | |
US60/214,358 | 2000-06-28 | ||
US21563800P | 2000-06-30 | 2000-06-30 | |
US60/215,638 | 2000-06-30 | ||
US27999701P | 2001-03-30 | 2001-03-30 | |
US60/279,997 | 2001-03-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002000879A2 WO2002000879A2 (en) | 2002-01-03 |
WO2002000879A3 true WO2002000879A3 (en) | 2002-09-06 |
Family
ID=27395978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/020553 WO2002000879A2 (en) | 2000-06-28 | 2001-06-27 | Methods for producing modified glycoproteins |
Country Status (15)
Country | Link |
---|---|
US (13) | US7029872B2 (en) |
EP (5) | EP2339013B1 (en) |
JP (2) | JP2004501642A (en) |
KR (1) | KR100787073B1 (en) |
AT (2) | ATE309385T1 (en) |
AU (2) | AU2001276842B2 (en) |
CA (1) | CA2412701A1 (en) |
CY (1) | CY1109639T1 (en) |
DE (2) | DE60139720D1 (en) |
DK (2) | DK1297172T3 (en) |
ES (2) | ES2252261T3 (en) |
MX (1) | MXPA03000105A (en) |
NZ (1) | NZ523476A (en) |
PT (1) | PT1522590E (en) |
WO (1) | WO2002000879A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8877462B2 (en) | 2000-06-28 | 2014-11-04 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
US8986949B2 (en) | 2003-02-20 | 2015-03-24 | Glycofi, Inc. | Endomannosidases in the modification of glycoproteins in eukaryotes |
US9574218B2 (en) | 2001-01-19 | 2017-02-21 | Phyton Holdings, Llc | Method of co-expressing galactosyltransferase and a glycoprotein in a transgenic plant cell and sialylating the glycoprotein for production of glycoprotein having human-type sugar chain |
Families Citing this family (466)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5545553A (en) * | 1994-09-26 | 1996-08-13 | The Rockefeller University | Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them |
NZ512185A (en) | 1998-12-09 | 2004-02-27 | Dow Chemical Co | A method for manufacturing glycoproteins having human- type glycosylation in plant cells |
ES2288882T3 (en) | 1999-10-26 | 2008-02-01 | Plant Research International B.V. | GLAMMOSILATION OF MAMMER TYPE IN PLANTS. |
DK1283265T3 (en) * | 2000-05-17 | 2009-11-09 | Mitsubishi Tanabe Pharma Corp | Process for producing protein with reduction of mannose phosphate in the sugar chain and glycoprotein prepared thereby |
US7598055B2 (en) * | 2000-06-28 | 2009-10-06 | Glycofi, Inc. | N-acetylglucosaminyltransferase III expression in lower eukaryotes |
US7625756B2 (en) | 2000-06-28 | 2009-12-01 | GycoFi, Inc. | Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells |
US7863020B2 (en) | 2000-06-28 | 2011-01-04 | Glycofi, Inc. | Production of sialylated N-glycans in lower eukaryotes |
US7795002B2 (en) | 2000-06-28 | 2010-09-14 | Glycofi, Inc. | Production of galactosylated glycoproteins in lower eukaryotes |
US20060024304A1 (en) * | 2000-06-28 | 2006-02-02 | Gerngross Tillman U | Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform |
US20060029604A1 (en) * | 2000-06-28 | 2006-02-09 | Gerngross Tillman U | Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform |
AU2001276842B2 (en) * | 2000-06-28 | 2007-04-26 | Glycofi, Inc. | Methods for producing modified glycoproteins |
US8697394B2 (en) | 2000-06-28 | 2014-04-15 | Glycofi, Inc. | Production of modified glycoproteins having multiple antennary structures |
US20060034828A1 (en) * | 2000-06-28 | 2006-02-16 | Gerngross Tillman U | Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform |
US20060034830A1 (en) * | 2000-06-28 | 2006-02-16 | Gerngross Tillman U | Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform |
AU2001277658B2 (en) * | 2000-06-30 | 2006-10-19 | Research Corporation Technologies, Inc. | Protein glycosylation modification in pichia pastoris |
AU2002231736A1 (en) | 2000-12-22 | 2002-07-08 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. | Use of repulsive guidance molecule (rgm) and its modulators |
TWI377253B (en) | 2001-04-16 | 2012-11-21 | Martek Biosciences Corp | Product and process for transformation of thraustochytriales microorganisms |
AU2004236174B2 (en) * | 2001-10-10 | 2011-06-02 | Novo Nordisk A/S | Glycopegylation methods and proteins/peptides produced by the methods |
US7297511B2 (en) * | 2001-10-10 | 2007-11-20 | Neose Technologies, Inc. | Interferon alpha: remodeling and glycoconjugation of interferon alpha |
US7226903B2 (en) | 2001-10-10 | 2007-06-05 | Neose Technologies, Inc. | Interferon beta: remodeling and glycoconjugation of interferon beta |
US7439043B2 (en) * | 2001-10-10 | 2008-10-21 | Neose Technologies, Inc. | Galactosyl nucleotide sugars |
US7265084B2 (en) * | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycopegylation methods and proteins/peptides produced by the methods |
US7696163B2 (en) | 2001-10-10 | 2010-04-13 | Novo Nordisk A/S | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
ES2538342T3 (en) * | 2001-10-10 | 2015-06-19 | Ratiopharm Gmbh | Remodeling and glycoconjugation of follicle stimulating hormone (FSH) |
US8008252B2 (en) * | 2001-10-10 | 2011-08-30 | Novo Nordisk A/S | Factor VII: remodeling and glycoconjugation of Factor VII |
US7179617B2 (en) | 2001-10-10 | 2007-02-20 | Neose Technologies, Inc. | Factor IX: remolding and glycoconjugation of Factor IX |
US7399613B2 (en) | 2001-10-10 | 2008-07-15 | Neose Technologies, Inc. | Sialic acid nucleotide sugars |
US7795210B2 (en) | 2001-10-10 | 2010-09-14 | Novo Nordisk A/S | Protein remodeling methods and proteins/peptides produced by the methods |
US7125843B2 (en) | 2001-10-19 | 2006-10-24 | Neose Technologies, Inc. | Glycoconjugates including more than one peptide |
US7214660B2 (en) * | 2001-10-10 | 2007-05-08 | Neose Technologies, Inc. | Erythropoietin: remodeling and glycoconjugation of erythropoietin |
US7173003B2 (en) | 2001-10-10 | 2007-02-06 | Neose Technologies, Inc. | Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF |
US7157277B2 (en) | 2001-11-28 | 2007-01-02 | Neose Technologies, Inc. | Factor VIII remodeling and glycoconjugation of Factor VIII |
EP2305311A3 (en) | 2001-10-10 | 2011-07-20 | BioGeneriX AG | Glycoconjugation of peptides |
US7265085B2 (en) * | 2001-10-10 | 2007-09-04 | Neose Technologies, Inc. | Glycoconjugation methods and proteins/peptides produced by the methods |
US7473680B2 (en) * | 2001-11-28 | 2009-01-06 | Neose Technologies, Inc. | Remodeling and glycoconjugation of peptides |
US20060024292A1 (en) * | 2001-12-27 | 2006-02-02 | Gerngross Tillman U | Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform |
EP2359685B1 (en) | 2001-12-27 | 2013-12-04 | GlycoFi, Inc. | Methods to engineer mammalian-type carbohydrate structures |
US20060034829A1 (en) * | 2001-12-27 | 2006-02-16 | Gerngross Tillman U | Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform |
US6964784B2 (en) * | 2002-03-07 | 2005-11-15 | Optigenex, Inc. | Method of preparation and composition of a water soluble extract of the bioactive component of the plant species uncaria for enhancing immune, anti-inflammatory, anti-tumor and dna repair processes of warm blooded animals |
CA2799805C (en) * | 2002-03-19 | 2016-05-17 | Stichting Dienst Landbouwkundig Onderzoek | Optimizing glycan processing in plants |
US7897842B2 (en) | 2002-03-19 | 2011-03-01 | Plant Research International B.V. | GnTIII expression in plants |
ATE420198T1 (en) * | 2002-04-26 | 2009-01-15 | Kirin Pharma Kk | METHYLOTROPHIC YEAST THAT PRODUCES A MAMMAL SUGAR CHAIN |
DE60336555D1 (en) | 2002-06-21 | 2011-05-12 | Novo Nordisk Healthcare Ag | PEGYLATED GLYCO FORMS OF FACTOR VII |
US7252933B2 (en) | 2002-06-26 | 2007-08-07 | Flanders Interuniversity Institute For Biotechnology | Protein glycosylation modification in methylotrophic yeast |
KR20040004089A (en) * | 2002-06-29 | 2004-01-13 | 한국생명공학연구원 | Hansenula polymorpha mutant strains with defect in outer chain biosynthesis and the production of recombinant glycoproteins using the same strains |
AU2003263717A1 (en) * | 2002-09-25 | 2004-04-19 | Astrazeneca Ab | A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES |
AR042145A1 (en) | 2002-11-27 | 2005-06-08 | Dow Agrociences Llc | IMMUNOGLOBULIN PRODUCTION IN PLANTS WITH A REDUCED FUCOCILATION |
RU2407796C2 (en) * | 2003-01-22 | 2010-12-27 | Гликарт Биотекнолоджи АГ | FUSION DESIGNS AND THEIR APPLICATION FOR PRODUCING ANTIBODIES WITH HIGH BINDING AFFINITY OF Fc-RECEPTOR AND EFFECTOR FUNCTION |
ES2542885T3 (en) | 2003-01-22 | 2015-08-12 | Roche Glycart Ag | Fusion constructs and use thereof to produce antibodies with greater affinity for Fc receptor binding and effector function |
DE10303974A1 (en) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid β (1-42) oligomers, process for their preparation and their use |
AU2012227297B2 (en) * | 2003-02-20 | 2013-11-14 | Glycofi, Inc. | Combinatorial DNA Library for Producing Modified N-Glycans in Lower Eukaryotes |
BRPI0408358A (en) | 2003-03-14 | 2006-03-21 | Neose Technologies Inc | branched water-soluble polymers and their conjugates |
US7691603B2 (en) * | 2003-04-09 | 2010-04-06 | Novo Nordisk A/S | Intracellular formation of peptide conjugates |
US8791070B2 (en) | 2003-04-09 | 2014-07-29 | Novo Nordisk A/S | Glycopegylated factor IX |
EP1624847B1 (en) | 2003-05-09 | 2012-01-04 | BioGeneriX AG | Compositions and methods for the preparation of human growth hormone glycosylation mutants |
WO2005012484A2 (en) | 2003-07-25 | 2005-02-10 | Neose Technologies, Inc. | Antibody-toxin conjugates |
US9357755B2 (en) * | 2003-10-28 | 2016-06-07 | The University Of Wyoming | Production of human glycosylated proteins in silk worm |
US20070067855A1 (en) * | 2003-10-28 | 2007-03-22 | Chesapeake Perl, Inc. | Production of human glycosylated proteins in transgenic insects |
US20050100965A1 (en) | 2003-11-12 | 2005-05-12 | Tariq Ghayur | IL-18 binding proteins |
US7507573B2 (en) * | 2003-11-14 | 2009-03-24 | Vib, Vzw | Modification of protein glycosylation in methylotrophic yeast |
US20080305992A1 (en) | 2003-11-24 | 2008-12-11 | Neose Technologies, Inc. | Glycopegylated erythropoietin |
ES2445948T3 (en) * | 2003-11-24 | 2014-03-06 | Ratiopharm Gmbh | Glycopegylated Erythropoietin |
US8633157B2 (en) | 2003-11-24 | 2014-01-21 | Novo Nordisk A/S | Glycopegylated erythropoietin |
US7956032B2 (en) * | 2003-12-03 | 2011-06-07 | Novo Nordisk A/S | Glycopegylated granulocyte colony stimulating factor |
US20080318850A1 (en) * | 2003-12-03 | 2008-12-25 | Neose Technologies, Inc. | Glycopegylated Factor Ix |
US20060040856A1 (en) | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
AU2004311545B2 (en) * | 2003-12-24 | 2008-11-06 | Glycofi, Inc. | Methods for eliminating mannosylphosphorylation of glycans in the production of glycoproteins |
JP5743368B2 (en) | 2004-01-08 | 2015-07-01 | ラショファーム ゲーエムベーハー | O-linked glycosylation of peptides |
KR100604994B1 (en) | 2004-01-30 | 2006-07-26 | 한국생명공학연구원 | A novel Hansenula polymorpha gene coding for ?1,6- mannosyltransferase and process for the production of recombinant glycoproteins with Hansenula polymorpha mutant strain deficient in the same gene |
WO2005090552A2 (en) * | 2004-03-17 | 2005-09-29 | Glycofi, Inc. | Method of engineering a cytidine monophosphate-sialic acid synthetic pathway in fungi and yeast |
WO2005089047A2 (en) * | 2004-03-18 | 2005-09-29 | Glycofi, Inc. | Glycosylated glucocerebrosidase expression in fungal hosts |
AU2005233387B2 (en) * | 2004-04-15 | 2011-05-26 | Glycofi, Inc. | Production of galactosylated glycoproteins in lower eukaryotes |
US7465577B2 (en) * | 2004-04-29 | 2008-12-16 | Glycofi, Inc. | Methods for reducing or eliminating α-mannosidase resistant glycans for the production of glycoproteins |
JP5752582B2 (en) * | 2004-04-29 | 2015-07-22 | グライコフィ, インコーポレイテッド | Methods for reducing or eliminating alpha-mannosidase resistant glycans in the production of glycoproteins |
ES2339953T5 (en) | 2004-05-04 | 2020-05-06 | Novo Nordisk Healthcare Ag | O-linked factor VII glycoforms and method of manufacture |
US20080300173A1 (en) | 2004-07-13 | 2008-12-04 | Defrees Shawn | Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1] |
EP1771479A1 (en) * | 2004-07-21 | 2007-04-11 | Glycofi, Inc. | IMMUNOGLOBULINS COMPRISING PREDOMINANTLY A GlCNACMAN5GLCNAC2 GLYCOFORM |
WO2006026992A1 (en) * | 2004-09-07 | 2006-03-16 | Novozymes A/S | Altered structure of n-glycans in a fungus |
US8268967B2 (en) | 2004-09-10 | 2012-09-18 | Novo Nordisk A/S | Glycopegylated interferon α |
JP2008514215A (en) * | 2004-09-29 | 2008-05-08 | ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト | Modified protein |
EP3061461A1 (en) | 2004-10-29 | 2016-08-31 | ratiopharm GmbH | Remodeling and glycopegylation of fibroblast growth factor (fgf) |
WO2006071856A2 (en) * | 2004-12-23 | 2006-07-06 | Glycofi, Inc. | Immunoglobulins comprising predominantly a man5glcnac2 glycoform |
JP4951527B2 (en) | 2005-01-10 | 2012-06-13 | バイオジェネリックス アーゲー | GlycoPEGylated granulocyte colony stimulating factor |
CN101137757A (en) * | 2005-03-07 | 2008-03-05 | 植物研究国际公司 | Glycoengineering in mushrooms |
JP2008538181A (en) * | 2005-03-30 | 2008-10-16 | ネオス テクノロジーズ インコーポレイテッド | Manufacturing method for producing peptides grown in insect cell systems |
WO2006121569A2 (en) * | 2005-04-08 | 2006-11-16 | Neose Technologies, Inc. | Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
EP1888098A2 (en) | 2005-05-25 | 2008-02-20 | Neose Technologies, Inc. | Glycopegylated erythropoietin formulations |
JP5216580B2 (en) | 2005-05-25 | 2013-06-19 | ノヴォ ノルディスク アー/エス | Glycopegylated factor IX |
KR20130080058A (en) * | 2005-06-30 | 2013-07-11 | 아보트 러보러터리즈 | Il-12/p40 binding proteins |
EP1937719A4 (en) * | 2005-08-19 | 2010-11-24 | Novo Nordisk As | Glycopegylated factor vii and factor viia |
US20070105755A1 (en) | 2005-10-26 | 2007-05-10 | Neose Technologies, Inc. | One pot desialylation and glycopegylation of therapeutic peptides |
EP2500354A3 (en) | 2005-08-19 | 2012-10-24 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
NZ612578A (en) | 2005-08-19 | 2014-11-28 | Abbvie Inc | Dual variable domain immunoglobin and uses thereof |
US20090215992A1 (en) * | 2005-08-19 | 2009-08-27 | Chengbin Wu | Dual variable domain immunoglobulin and uses thereof |
US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
WO2007028144A2 (en) * | 2005-09-02 | 2007-03-08 | Glycofi, Inc | Immunoglobulins comprising predominantly a glcnacman3glcnac2 glycoform |
AU2005336263A1 (en) * | 2005-09-09 | 2007-03-15 | Glycofi, Inc. | Immunoglobulin comprising predominantly a man7GlcNAc2, Man8GlcNAc2 glycoform |
US8202523B2 (en) * | 2005-09-22 | 2012-06-19 | ProSci, Inc. | Glycosylated polypeptides produced in yeast mutants and methods of use thereof |
EP1928905B1 (en) | 2005-09-30 | 2015-04-15 | AbbVie Deutschland GmbH & Co KG | Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use |
KR101105718B1 (en) * | 2005-10-27 | 2012-01-17 | 한국생명공학연구원 | A novel Hansenula polymorpha gene coding for dolichyl-phosphate-mannose dependent ?-1,3-mannosyltransferase and process for the production of recombinant glycoproteins with Hansenula polymorpha mutant strain deficient in the same gene |
US20090048440A1 (en) | 2005-11-03 | 2009-02-19 | Neose Technologies, Inc. | Nucleotide Sugar Purification Using Membranes |
WO2007061631A2 (en) * | 2005-11-15 | 2007-05-31 | Glycofi, Inc | Production of glycoproteins with reduced o-glycosylation |
EP2289909B1 (en) | 2005-11-30 | 2014-10-29 | AbbVie Inc. | Screening method, process for purifying of non-diffusible a-beta oligomers, selective antibodies against said non-diffusible a-beta oligomers and a process for manufacturing of said antibodies |
CN102898519B (en) | 2005-11-30 | 2015-10-28 | Abbvie公司 | Monoclonal antibody of anti-amyloid beta protein and uses thereof |
US20090060921A1 (en) * | 2006-01-17 | 2009-03-05 | Biolex Therapeutics, Inc. | Glycan-optimized anti-cd20 antibodies |
ES2395842T3 (en) * | 2006-01-17 | 2013-02-15 | Synthon Biopharmaceuticals B.V. | Compositions and methods for humanization and optimization of N-glycans in plants |
US20070190057A1 (en) | 2006-01-23 | 2007-08-16 | Jian Wu | Methods for modulating mannose content of recombinant proteins |
US20090181041A1 (en) * | 2006-01-23 | 2009-07-16 | Jan Holgersson | Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof |
EP2781524A1 (en) * | 2006-01-26 | 2014-09-24 | Recopharma AB | Compositions and methods for inhibiting viral adhesion |
DK2004819T3 (en) * | 2006-04-05 | 2015-10-05 | Danisco Us Inc | FILAMENTOUS FUNGI WITH REDUCED CONTENT OF UDP-GALACTOFURANOSE |
BRPI0710482A2 (en) * | 2006-04-21 | 2011-08-16 | Wyeth Corp | methods for selecting high throughput cell lines |
US7851438B2 (en) * | 2006-05-19 | 2010-12-14 | GlycoFi, Incorporated | Erythropoietin compositions |
CN101535340B (en) * | 2006-05-19 | 2013-05-01 | 格利科菲公司 | Erythropoietin compositions |
ATE516346T1 (en) * | 2006-05-24 | 2011-07-15 | Univ Provence Aix Marseille 1 | PREPARATION AND USES OF CHIMERIC GLYCOSYL TRANSFERASES WITH GENE SEQUENCES ENCODING OPTIMIZED GLYCOSYLATION ACTIVITY |
AR078117A1 (en) | 2006-06-20 | 2011-10-19 | Protech Pharma S A | A RECOMBINANT MUTEIN OF THE GLICOSILATED HUMAN ALPHA INTERFERON, A CODIFYING GENE FOR SUCH MUTEIN, A METHOD OF PRODUCTION OF SUCH GENE, A METHOD FOR OBTAINING A EUCARIOTE CELL MANUFACTURING THIS MUTEINE, A METHOD FOR A MUTE DIFFERENT PROCEDURE |
JP2009544327A (en) * | 2006-07-21 | 2009-12-17 | ノヴォ ノルディスク アー/エス | Glycosylation of peptides with O-linked glycosylation sequences |
US7879799B2 (en) * | 2006-08-10 | 2011-02-01 | Institute For Systems Biology | Methods for characterizing glycoproteins and generating antibodies for same |
KR101544108B1 (en) | 2006-09-08 | 2015-08-13 | 애브비 바하마스 리미티드 | -13 Interleukin-13 binding proteins |
JP2010505874A (en) | 2006-10-03 | 2010-02-25 | ノヴォ ノルディスク アー/エス | Purification method for polypeptide conjugates |
WO2008063776A2 (en) * | 2006-10-12 | 2008-05-29 | Genentech, Inc. | Antibodies to lymphotoxin-alpha |
EP1916259A1 (en) | 2006-10-26 | 2008-04-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Anti-glycoprotein VI SCFV fragment for treatment of thrombosis |
US20080207487A1 (en) * | 2006-11-02 | 2008-08-28 | Neose Technologies, Inc. | Manufacturing process for the production of polypeptides expressed in insect cell-lines |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
AR064464A1 (en) * | 2006-12-22 | 2009-04-01 | Genentech Inc | ANTIBODIES ANTI - INSULINAL GROWTH FACTOR RECEIVER |
FR2912154B1 (en) | 2007-02-02 | 2012-11-02 | Glycode | GENETICALLY MODIFIED YEASTS FOR THE PRODUCTION OF HOMOGENEOUS GLYCOPROTEINS |
AU2008214359B2 (en) | 2007-02-05 | 2014-01-16 | Apellis Pharmaceuticals, Inc. | Local complement inhibition for treatment of complement-mediated disorders |
EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
EP2134834B1 (en) | 2007-03-07 | 2013-04-17 | GlycoFi, Inc. | Production of glycoproteins with modified fucosylation |
CA2679986C (en) | 2007-03-08 | 2018-03-06 | Martin Lackmann | Epha3 antibodies for the treatment of solid tumors |
JP5721951B2 (en) | 2007-03-22 | 2015-05-20 | バイオジェン アイデック マサチューセッツ インコーポレイテッド | Binding proteins that specifically bind to CD154, including antibodies, antibody derivatives, and antibody fragments, and uses thereof |
EP2508613A3 (en) | 2007-04-03 | 2012-11-28 | Oxyrane UK Limited | Glycosylation of molecules |
ES2406267T3 (en) | 2007-04-03 | 2013-06-06 | Biogenerix Ag | Treatment methods using glycopegylated G-CSF |
US20080256056A1 (en) * | 2007-04-10 | 2008-10-16 | Yahoo! Inc. | System for building a data structure representing a network of users and advertisers |
MX341988B (en) | 2007-04-17 | 2016-09-08 | Stichting Dienst Landbouwkunding Onderzoek | Mammalian-type glycosylation in plants by expression of non-mammalian glycosyltransferases. |
WO2008137915A2 (en) | 2007-05-07 | 2008-11-13 | Medimmune, Llc | Anti-icos antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
US20090053167A1 (en) * | 2007-05-14 | 2009-02-26 | Neose Technologies, Inc. | C-, S- and N-glycosylation of peptides |
HUE036885T2 (en) | 2007-05-14 | 2018-08-28 | Astrazeneca Ab | Methods of reducing basophil levels |
US20090232801A1 (en) * | 2007-05-30 | 2009-09-17 | Abbot Laboratories | Humanized Antibodies Which Bind To AB (1-42) Globulomer And Uses Thereof |
PE20090329A1 (en) * | 2007-05-30 | 2009-03-27 | Abbott Lab | HUMANIZED ANTIBODIES AGAINST GLOBULOMER AB (20-42) AND ITS USES |
CN101778859B (en) | 2007-06-12 | 2014-03-26 | 诺和诺德公司 | Improved process for the production of nucleotide sugars |
US8207112B2 (en) | 2007-08-29 | 2012-06-26 | Biogenerix Ag | Liquid formulation of G-CSF conjugate |
US8637435B2 (en) * | 2007-11-16 | 2014-01-28 | Merck Sharp & Dohme Corp. | Eukaryotic cell display systems |
US9133464B2 (en) | 2007-12-19 | 2015-09-15 | Glycofi, Inc. | Yeast strains for protein production |
WO2009089154A2 (en) * | 2008-01-03 | 2009-07-16 | Cornell Research Foundation, Inc. | Glycosylated protein expression in prokaryotes |
CA2714166A1 (en) * | 2008-02-20 | 2009-08-27 | Glycofi, Inc. | Vectors and yeast strains for protein production |
ES2476690T3 (en) | 2008-02-27 | 2014-07-15 | Novo Nordisk A/S | Factor VIII conjugated molecules |
US8962803B2 (en) | 2008-02-29 | 2015-02-24 | AbbVie Deutschland GmbH & Co. KG | Antibodies against the RGM A protein and uses thereof |
WO2009111183A1 (en) * | 2008-03-03 | 2009-09-11 | Glycofi, Inc. | Surface display of recombinant proteins in lower eukaryotes |
JP2011512875A (en) * | 2008-03-11 | 2011-04-28 | ジェネンテック, インコーポレイテッド | Antibody with enhanced ADCC function |
BRPI0910482A2 (en) | 2008-04-29 | 2019-09-24 | Abbott Lab | double variable domain immunoglobins and their uses |
ES2620285T3 (en) | 2008-05-02 | 2017-06-28 | Novartis Ag | Binding molecules based on improved fibronectin and their uses |
EP2116556B1 (en) * | 2008-05-09 | 2016-03-23 | AbbVie Deutschland GmbH & Co KG | Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof |
MX2010013059A (en) | 2008-05-30 | 2010-12-20 | Glycofi Inc | Yeast strain for the production of proteins with terminal alpha-1,3-linked galactose. |
EP2297209A4 (en) | 2008-06-03 | 2012-08-01 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
SG191625A1 (en) | 2008-06-03 | 2013-07-31 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
CN104829718A (en) | 2008-07-08 | 2015-08-12 | 艾伯维公司 | Prostaglandin E2 binding proteins and uses thereof |
US8822645B2 (en) | 2008-07-08 | 2014-09-02 | Abbvie Inc. | Prostaglandin E2 dual variable domain immunoglobulins and uses thereof |
US8067339B2 (en) | 2008-07-09 | 2011-11-29 | Merck Sharp & Dohme Corp. | Surface display of whole antibodies in eukaryotes |
US8815580B2 (en) | 2008-08-08 | 2014-08-26 | Vib Vzw | Cells producing glycoproteins having altered glycosylation patterns and method and use thereof |
AU2009282228A1 (en) | 2008-08-12 | 2010-02-18 | Glycofi, Inc. | Improved vectors and yeast strains for protein production: Ca2+ ATPase overexpression |
US20100120701A1 (en) | 2008-09-25 | 2010-05-13 | Glycosyn, Inc. | Compositions and Methods For Engineering Probiotic Yeast |
EP2341139B1 (en) | 2008-10-01 | 2016-05-04 | Asahi Glass Company, Limited | Host, transformant, method for producing the transformant, and method for producing heterogeneous protein containing o-glycoside type sugar chain |
ES2719496T3 (en) | 2008-11-12 | 2019-07-10 | Medimmune Llc | Antibody formulation |
SG171812A1 (en) * | 2008-12-04 | 2011-07-28 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
US20110300584A1 (en) | 2008-12-19 | 2011-12-08 | Jennewein Biotechnologie Gmbh | Synthesis of fucosylated compounds |
BRPI0923191A2 (en) | 2008-12-19 | 2016-02-16 | Momenta Pharmaceuticals Inc | Modified glycan related methods |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
US20110165063A1 (en) * | 2009-01-29 | 2011-07-07 | Abbott Laboratories | Il-1 binding proteins |
US8383778B2 (en) * | 2009-01-29 | 2013-02-26 | Abbvie Inc. | IL-1 binding proteins |
US8030026B2 (en) | 2009-02-24 | 2011-10-04 | Abbott Laboratories | Antibodies to troponin I and methods of use thereof |
EP2401378B1 (en) | 2009-02-25 | 2013-08-14 | Merck Sharp & Dohme Corp. | Metabolic engineering of a galactose assimilation pathway in the glycoengineered yeast pichia pastoris |
JP5836807B2 (en) | 2009-03-05 | 2015-12-24 | アッヴィ・インコーポレイテッド | IL-17 binding protein |
EP2403879A1 (en) | 2009-03-06 | 2012-01-11 | Kalobios Pharmaceuticals, Inc. | Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3 |
US8283162B2 (en) | 2009-03-10 | 2012-10-09 | Abbott Laboratories | Antibodies relating to PIVKAII and uses thereof |
ES2752196T3 (en) | 2009-03-16 | 2020-04-03 | Dsm Ip Assets Bv | Protein production in microorganisms of the Labyrinthulomycota edge |
UA108349C2 (en) * | 2009-03-16 | 2015-04-27 | Сефалон Острейліа Пті Лтд | Humanized antibody with antitumor activity |
BRPI1016055A2 (en) | 2009-04-27 | 2016-05-10 | Novartis Ag | composition and methods of use for il-12 receptor beta-subunit specific therapeutic antibodies |
NO2424895T3 (en) | 2009-04-27 | 2018-02-03 | ||
AU2010254215A1 (en) * | 2009-05-26 | 2011-12-01 | Momenta Pharmaceuticals, Inc. | Production of glycoproteins |
WO2010138184A2 (en) * | 2009-05-27 | 2010-12-02 | Synageva Biopharma Corp. | Avian derived antibodies |
US20120121630A1 (en) * | 2009-07-24 | 2012-05-17 | Bryan Janine T | Recombinant ectodomain expression of herpes simplex virus glycoproteins in yeast |
CA2952742A1 (en) | 2009-08-29 | 2011-03-03 | Abbvie Inc. | Therapeutic dll4 binding proteins |
KR20120060877A (en) | 2009-09-01 | 2012-06-12 | 아보트 러보러터리즈 | Dual variable domain immunoglobulins and uses thereof |
WO2011029823A1 (en) | 2009-09-09 | 2011-03-17 | Novartis Ag | Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells |
CA2775938C (en) | 2009-09-29 | 2021-08-10 | Oxyrane Uk Limited | Hydrolysis of mannose-1-phospho-6-mannose linkage to phospho-6-mannose |
DK2488554T3 (en) | 2009-10-14 | 2019-09-02 | Humanigen Inc | ANTIBODIES AGAINST EPHA3 |
JP2013507928A (en) | 2009-10-15 | 2013-03-07 | アボット・ラボラトリーズ | Dual variable domain immunoglobulins and uses thereof |
BR112012008862A2 (en) | 2009-10-16 | 2019-09-24 | Merck Sharp & Dohme | methods for producing a recombinant glycoprotein and a mature human erythropoietin, and, composition |
UY32979A (en) * | 2009-10-28 | 2011-02-28 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
WO2011051327A2 (en) | 2009-10-30 | 2011-05-05 | Novartis Ag | Small antibody-like single chain proteins |
EP2494050A4 (en) * | 2009-10-30 | 2013-10-30 | Merck Sharp & Dohme | Granulocyte-colony stimulating factor produced in glycoengineered pichia pastoris |
CN102686731A (en) | 2009-10-30 | 2012-09-19 | 默沙东公司 | Methods for the production of recombinant proteins with improved secretion efficiencies |
AU2010313492B2 (en) | 2009-10-30 | 2014-05-29 | Merck Sharp & Dohme Corp. | Method for producing therapeutic proteins in Pichia pastoris lacking dipeptidyl aminopeptidase activity |
WO2011053707A1 (en) | 2009-10-31 | 2011-05-05 | Abbott Laboratories | Antibodies to receptor for advanced glycation end products (rage) and uses thereof |
WO2011051466A1 (en) | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
WO2011054030A1 (en) | 2009-11-05 | 2011-05-12 | Cephalon Australia Pty Ltd | Treatment of cancer involving mutated kras or braf genes |
WO2011061629A2 (en) | 2009-11-19 | 2011-05-26 | Oxyrane Uk Limited | Yeast strains producing mammalian-like complex n-glycans |
AU2010325943A1 (en) | 2009-12-02 | 2012-06-21 | Acceleron Pharma Inc. | Compositions and methods for increasing serum half-life of Fc fusion proteins. |
ES2562832T3 (en) | 2009-12-08 | 2016-03-08 | Abbvie Deutschland Gmbh & Co Kg | Monoclonal antibodies against the RGM protein for use in the treatment of degeneration of the retinal nerve fiber layer |
AU2010334974A1 (en) | 2009-12-22 | 2012-07-12 | Novartis Ag | Tetravalent CD47-antibody constant region fusion protein for use in therapy |
US20110195448A1 (en) * | 2009-12-28 | 2011-08-11 | James Casey Lippmeier | Recombinant Thraustochytrids that Grow on Xylose, and Compositions, Methods of Making, and Uses Thereof |
IN2012DN06277A (en) * | 2009-12-28 | 2015-09-25 | Dsm Ip Assets Bv | |
AU2010339544B2 (en) * | 2009-12-28 | 2015-11-12 | Merial Limited | Production of hemagglutinin-neuraminidase protein in microalgae |
WO2011092233A1 (en) | 2010-01-29 | 2011-08-04 | Novartis Ag | Yeast mating to produce high-affinity combinations of fibronectin-based binders |
KR101930961B1 (en) * | 2010-02-24 | 2018-12-19 | 머크 샤프 앤드 돔 코포레이션 | Method for increasing n-glycosylation site occupancy on therapeutic glycoproteins produced in pichia pastoris |
WO2011109298A2 (en) | 2010-03-02 | 2011-09-09 | Abbott Laboratories | Therapeutic dll4 binding proteins |
BR112012025645A2 (en) | 2010-04-07 | 2017-12-12 | Momenta Pharmaceuticals Inc | high mannose glycans. |
CN102933601B (en) | 2010-04-15 | 2016-06-08 | Abbvie公司 | Amyloid beta is in conjunction with albumen |
WO2011139714A2 (en) | 2010-04-26 | 2011-11-10 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-trna synthetase |
US8961960B2 (en) | 2010-04-27 | 2015-02-24 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of isoleucyl tRNA synthetases |
EP2563911B1 (en) | 2010-04-28 | 2021-07-21 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases |
US9034320B2 (en) | 2010-04-29 | 2015-05-19 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Valyl-tRNA synthetases |
AU2011248490B2 (en) | 2010-04-29 | 2016-11-10 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Asparaginyl tRNA synthetases |
US8981045B2 (en) | 2010-05-03 | 2015-03-17 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-tRNA synthetases |
EP2566495B1 (en) | 2010-05-03 | 2017-03-01 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-trna synthetases |
JP5976638B2 (en) | 2010-05-03 | 2016-08-23 | エータイアー ファーマ, インコーポレイテッド | Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of arginyl tRNA synthetase |
US9062302B2 (en) | 2010-05-04 | 2015-06-23 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex |
TWI615405B (en) | 2010-05-14 | 2018-02-21 | 艾伯維有限公司 | Il-1 binding proteins |
EP2568996B1 (en) | 2010-05-14 | 2017-10-04 | aTyr Pharma, Inc. | Therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-beta-trna synthetases |
RU2604811C2 (en) | 2010-05-27 | 2016-12-10 | Мерк Шарп Энд Домэ Корп. | Method for preparing antibodies having improved properties |
AU2011258106B2 (en) | 2010-05-27 | 2017-02-23 | Pangu Biopharma Limited | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases |
CN103118694B (en) | 2010-06-01 | 2016-08-03 | Atyr医药公司 | The discovery for the treatment of, diagnosis and the antibody compositions relevant to the protein fragments of lysyl-tRNA synzyme |
US20120009196A1 (en) | 2010-07-08 | 2012-01-12 | Abbott Laboratories | Monoclonal antibodies against hepatitis c virus core protein |
UY33492A (en) | 2010-07-09 | 2012-01-31 | Abbott Lab | IMMUNOGLOBULINS WITH DUAL VARIABLE DOMAIN AND USES OF THE SAME |
EP2593125B1 (en) | 2010-07-12 | 2017-11-01 | aTyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases |
US9120862B2 (en) | 2010-07-26 | 2015-09-01 | Abbott Laboratories | Antibodies relating to PIVKA-II and uses thereof |
EP2598638A2 (en) | 2010-07-30 | 2013-06-05 | Glycode | A yeast artificial chromosome carrying the mammalian glycosylation pathway |
CA2807014A1 (en) | 2010-08-03 | 2012-02-09 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
AU2011288412A1 (en) | 2010-08-13 | 2013-02-21 | Medimmune Limited | Monomeric polypeptides comprising variant Fc regions and methods of use |
US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
WO2012022734A2 (en) | 2010-08-16 | 2012-02-23 | Medimmune Limited | Anti-icam-1 antibodies and methods of use |
HUE058226T2 (en) | 2010-08-19 | 2022-07-28 | Zoetis Belgium S A | Anti-ngf antibodies and their use |
US9029506B2 (en) | 2010-08-25 | 2015-05-12 | Atyr Pharma, Inc. | Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of tyrosyl-tRNA synthetases |
US9046513B2 (en) | 2010-08-26 | 2015-06-02 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
JP6151183B2 (en) | 2010-09-29 | 2017-06-21 | オキシレイン ユーケー リミテッド | Mannosidase capable of uncapping and demannosylating phosphorylated N-glycans from mannose-1-phospho-6-mannose linkages and methods for promoting glycoprotein uptake by mammalian cells |
JP6131190B2 (en) | 2010-09-29 | 2017-05-17 | オキシレイン ユーケー リミテッド | Demannosylation of phosphorylated N-glycans |
WO2012045703A1 (en) | 2010-10-05 | 2012-04-12 | Novartis Ag | Anti-il12rbeta1 antibodies and their use in treating autoimmune and inflammatory disorders |
EP2646606B1 (en) | 2010-12-01 | 2018-10-10 | Merck Sharp&Dohme Corp. | Surface-anchored fc-bait antibody display system |
US9458240B2 (en) | 2010-12-10 | 2016-10-04 | Novartis Pharma Ag | Anti-BAFFR antibody formulations |
TW201249865A (en) | 2010-12-21 | 2012-12-16 | Abbott Lab | Dual variable domain immunoglobulins and uses thereof |
WO2012088094A2 (en) | 2010-12-21 | 2012-06-28 | Abbott Laboratories | Il-1 binding proteins |
WO2012109285A2 (en) | 2011-02-08 | 2012-08-16 | Medimmune, Llc | Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use |
CA2827732A1 (en) | 2011-02-25 | 2012-08-30 | Merck Sharp & Dohme Corp. | Yeast strain for the production of proteins with modified o-glycosylation |
EP2686671A4 (en) | 2011-03-12 | 2015-06-24 | Momenta Pharmaceuticals Inc | N-acetylhexosamine-containing n-glycans in glycoprotein products |
EP2895592A1 (en) | 2011-03-23 | 2015-07-22 | Société Industrielle Limousine d'Application Biologique (SILAB) | A yeast recombinant cell capable of producing gdp-fucose |
US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
WO2012156309A1 (en) | 2011-05-13 | 2012-11-22 | Millegen | Antibodies against her3 |
KR20140028013A (en) | 2011-05-25 | 2014-03-07 | 머크 샤프 앤드 돔 코포레이션 | Method for preparing fc-containing polypeptides having improved properties |
CA2838478A1 (en) | 2011-06-16 | 2012-12-20 | Novartis Ag | Soluble proteins for use as therapeutics |
KR20140104944A (en) | 2011-06-22 | 2014-08-29 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | Anti-axl antibodies and uses thereof |
FR2976811A1 (en) | 2011-06-22 | 2012-12-28 | Lfb Biotechnologies | USE OF A HIGH ADCC ANTI-CD20 ANTIBODY FOR THE TREATMENT OF WALDENSTROM'S DISEASE |
WO2012175692A1 (en) | 2011-06-22 | 2012-12-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-axl antibodies and uses thereof |
PL2726099T3 (en) | 2011-07-01 | 2018-12-31 | Novartis Ag | Method for treating metabolic disorders |
US20140341913A1 (en) | 2011-07-13 | 2014-11-20 | Abbvie Inc. | Methods and compositions for treating asthma using anti-il-13 antibodies |
WO2013013193A1 (en) | 2011-07-20 | 2013-01-24 | Zepteon, Incorporated | Polypeptide separation methods |
EP2765194B1 (en) * | 2011-10-03 | 2017-12-20 | National Institute of Advanced Industrial Science and Technology | Complex type sugar chain hydrolase |
JP2014534218A (en) | 2011-10-24 | 2014-12-18 | アッヴィ・インコーポレイテッド | Immunobinding agents targeting TNF |
US8999331B2 (en) | 2011-10-24 | 2015-04-07 | Abbvie Inc. | Immunobinders directed against sclerostin |
CN104203982B (en) | 2011-10-28 | 2018-08-31 | 特瓦制药澳大利亚私人有限公司 | Polypeptide construct and application thereof |
EP2771461B1 (en) | 2011-10-28 | 2019-12-04 | Merck Sharp & Dohme Corp. | Engineered lower eukaryotic host strains for recombinant protein expression |
WO2013066685A1 (en) * | 2011-10-31 | 2013-05-10 | Merck Sharp & Dohme Corp. | Engineered pichia strains with improved fermentation yield and n-glycosylation quality |
US9580509B2 (en) | 2011-11-07 | 2017-02-28 | Medimmune, Llc | Multispecific and multivalent binding proteins and uses thereof |
KR101457514B1 (en) | 2011-11-21 | 2014-11-03 | 한국생명공학연구원 | Sialyltransferase of Halocynthia rorentzi and a method for synthesis of sialoglycoconjugates using it |
EP2793932B1 (en) | 2011-12-20 | 2018-10-03 | Indiana University Research and Technology Corporation | Ctp-based insulin analogs for treatment of diabetes |
MX2014008101A (en) | 2011-12-30 | 2014-09-25 | Abbvie Inc | Dual variable domain immunoglobulins against il-13 and/or il-17. |
EP2617732A1 (en) | 2012-01-19 | 2013-07-24 | Vib Vzw | Tools and methods for expression of membrane proteins |
WO2013112922A1 (en) | 2012-01-27 | 2013-08-01 | AbbVie Deutschland GmbH & Co. KG | Composition and method for diagnosis and treatment of diseases associated with neurite degeneration |
CA2864300A1 (en) | 2012-02-16 | 2013-08-22 | Atyr Pharma, Inc. | Histidyl-trna synthetases for treating autoimmune and inflammatory diseases |
EP3628326B1 (en) | 2012-03-15 | 2024-02-28 | Oxyrane UK Limited | Methods and materials for treatment of pompe's disease |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013158279A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Protein purification methods to reduce acidic species |
US9505833B2 (en) | 2012-04-20 | 2016-11-29 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
CN104271816A (en) | 2012-05-11 | 2015-01-07 | 默沙东公司 | Surface anchored light chain bait antibody display system |
DK2852610T3 (en) | 2012-05-23 | 2018-09-03 | Glykos Finland Oy | PRODUCTION OF FUCOSYLED GLYCOPROTEIN |
WO2013181575A2 (en) | 2012-06-01 | 2013-12-05 | Momenta Pharmaceuticals, Inc. | Methods related to denosumab |
US9617334B2 (en) | 2012-06-06 | 2017-04-11 | Zoetis Services Llc | Caninized anti-NGF antibodies and methods thereof |
US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
WO2014004549A2 (en) | 2012-06-27 | 2014-01-03 | Amgen Inc. | Anti-mesothelin binding proteins |
UY34905A (en) | 2012-07-12 | 2014-01-31 | Abbvie Inc | IL-1 UNION PROTEINS |
US20150166664A1 (en) | 2012-07-18 | 2015-06-18 | Glycotope Gmbh | Novel therapeutic treatments with anti-her2 antibodies having a low fucosylation |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
JOP20200308A1 (en) | 2012-09-07 | 2017-06-16 | Novartis Ag | IL-18 binding molecules |
US20150275222A1 (en) | 2012-10-22 | 2015-10-01 | Bo Jiang | Crz1 mutant fungal cells |
DK2912162T3 (en) | 2012-10-23 | 2018-03-05 | Research Corporation Tech Inc | PICHIA PASTORIS TRIBES FOR PRODUCTION CONSIDERABLE UNIFORM GLYCAN STRUCTURE |
US20150246118A1 (en) | 2012-10-26 | 2015-09-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Lyve-1 antagonists for preventing or treating a pathological condition associated with lymphangiogenesis |
RU2636043C2 (en) | 2012-11-01 | 2017-11-17 | Эббви Инк. | Anti-vegf/dll4-immunoglobulins with double variable domains and their application |
EP2733153A1 (en) | 2012-11-15 | 2014-05-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the preparation of immunoconjugates and uses thereof |
CA2890048C (en) | 2012-12-03 | 2022-05-03 | Merck Sharp & Dohme Corp. | O-glycosylated carboxy terminal portion (ctp) peptide-based insulin and insulin analogues |
WO2014093240A1 (en) | 2012-12-10 | 2014-06-19 | The General Hospital Corporation | Bivalent il-2 fusion toxins |
WO2014090948A1 (en) | 2012-12-13 | 2014-06-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Serpin spn4a and biologically active derivatives thereof for use in the treatment of cancer |
CA2894225A1 (en) | 2012-12-17 | 2014-06-26 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Use of monoclonal antibodies for the treatment of inflammation and bacterial infections |
EP2934589B1 (en) | 2012-12-18 | 2021-01-13 | The Rockefeller University | Glycan-modified anti-cd4 antibodies for hiv prevention and therapy |
US9550986B2 (en) | 2012-12-21 | 2017-01-24 | Abbvie Inc. | High-throughput antibody humanization |
US9458244B2 (en) | 2012-12-28 | 2016-10-04 | Abbvie Inc. | Single chain multivalent binding protein compositions and methods |
EP2938637A2 (en) | 2012-12-28 | 2015-11-04 | AbbVie Inc. | Multivalent binding protein compositions |
CA2898415A1 (en) | 2013-01-16 | 2014-07-24 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders |
EP2948177A1 (en) | 2013-01-22 | 2015-12-02 | AbbVie Inc. | Methods for optimizing domain stability of binding proteins |
EP2953969B1 (en) | 2013-02-08 | 2019-08-28 | Novartis AG | Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders |
US9534041B2 (en) | 2013-02-12 | 2017-01-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies that neutralize a norovirus |
CA2900909A1 (en) | 2013-02-13 | 2014-08-21 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Highly galactosylated anti-tnf-.alpha. antibodies and uses thereof |
US9944689B2 (en) | 2013-03-07 | 2018-04-17 | The General Hospital Corporation | Human CTLA4 mutants and use thereof |
CN112851766A (en) | 2013-03-13 | 2021-05-28 | 美国政府(由卫生和人类服务部的部长所代表) | Pre-fusion RSV F proteins and uses thereof |
US9790478B2 (en) | 2013-03-14 | 2017-10-17 | Abbott Laboratories | HCV NS3 recombinant antigens and mutants thereof for improved antibody detection |
AU2014241743B2 (en) | 2013-03-14 | 2018-07-05 | Indiana University Research And Technology Corporation | Insulin-incretin conjugates |
MX2015012825A (en) | 2013-03-14 | 2016-06-10 | Abbott Lab | Hcv core lipid binding domain monoclonal antibodies. |
US9499614B2 (en) | 2013-03-14 | 2016-11-22 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosaccharides |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
CA2906421C (en) | 2013-03-14 | 2022-08-16 | George J. Dawson | Hcv antigen-antibody combination assay and methods and compositions for use therein |
EP2855533A4 (en) | 2013-03-15 | 2015-11-25 | Momenta Pharmaceuticals Inc | Methods related to ctla4-fc fusion proteins |
DK3460054T3 (en) | 2013-03-15 | 2021-01-18 | Atyr Pharma Inc | Histidyl-tRNA-synthetase-Fc conjugates |
BR112015023797A2 (en) | 2013-03-15 | 2017-10-24 | Abbvie Inc | dual specificity binding proteins directed against il-1b and / or il-17 |
WO2014173886A1 (en) | 2013-04-22 | 2014-10-30 | Glycotope Gmbh | Anti-cancer treatments with anti-egfr antibodies having a low fucosylation |
US11117975B2 (en) | 2013-04-29 | 2021-09-14 | Teva Pharmaceuticals Australia Pty Ltd | Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B |
MX370377B (en) | 2013-04-29 | 2019-12-11 | Teva Pharmaceuticals Australia Pty Ltd | Anti-cd38 antibodies and fusions to attenuated interferon alpha-2b. |
WO2014183052A1 (en) | 2013-05-09 | 2014-11-13 | The United States Of America, As Represented By The Secretary, Depart Of Health And Human Services | Single-domain vhh antibodies directed to norovirus gi.1 and gii.4 and their use |
WO2014186310A1 (en) | 2013-05-13 | 2014-11-20 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
CA2918300A1 (en) | 2013-08-14 | 2015-02-19 | Novartis Ag | Methods of treating sporadic inclusion body myositis |
US10202590B2 (en) | 2013-09-05 | 2019-02-12 | Vib Vzw | Cells producing Fc-containing molecules having altered glycosylation patterns and methods and use thereof |
WO2015044379A1 (en) | 2013-09-27 | 2015-04-02 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A dyrk1a polypeptide for use in preventing or treating metabolic disorders |
WO2015050959A1 (en) | 2013-10-01 | 2015-04-09 | Yale University | Anti-kit antibodies and methods of use thereof |
WO2015051010A1 (en) | 2013-10-02 | 2015-04-09 | Medimmune, Llc | Neutralizing anti-influenza a antibodies and uses thereof |
US9598667B2 (en) | 2013-10-04 | 2017-03-21 | Abbvie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
EP3058084A4 (en) | 2013-10-16 | 2017-07-05 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
EP3063275B1 (en) | 2013-10-31 | 2019-09-25 | Resolve Therapeutics, LLC | Therapeutic nuclease-albumin fusions and methods |
RU2704228C2 (en) | 2013-11-07 | 2019-10-24 | Инсерм (Институт Насьональ Де Ла Сант Эт Де Ла Решерш Медикаль) | Allosteric antibodies against human her3 non competitive for neuregulin and use thereof |
WO2015073884A2 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
FR3016633B1 (en) | 2014-01-17 | 2018-04-13 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | IMMUNOGLOBULIN ANTI-TOXIN CARBON |
JP6440636B2 (en) * | 2014-01-21 | 2018-12-19 | 株式会社シンプロジェン | Method for preparing unit DNA composition and method for preparing DNA conjugate |
AR099812A1 (en) | 2014-03-21 | 2016-08-17 | Abbvie Inc | ANTI-EGFR ANTIBODY AND DRUG ANTIBODIES AND CONJUGATES |
TW201622746A (en) | 2014-04-24 | 2016-07-01 | 諾華公司 | Methods of improving or accelerating physical recovery after surgery for hip fracture |
UA119352C2 (en) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | Combination of lenalidomide or pomalidomide and cd38 antibody-attenuated interferon-alpha constructs, and the use thereof |
US20170291939A1 (en) | 2014-06-25 | 2017-10-12 | Novartis Ag | Antibodies specific for il-17a fused to hyaluronan binding peptide tags |
CN113563462A (en) | 2014-07-15 | 2021-10-29 | 免疫医疗有限责任公司 | Neutralizing anti-influenza b antibodies and uses thereof |
CN108064266A (en) | 2014-07-21 | 2018-05-22 | 格利科斯芬兰公司 | The preparation of the glycoprotein with mammal sample N- glycan in filamentous fungi |
MX2017002229A (en) | 2014-08-19 | 2017-05-09 | Merck Sharp & Dohme | Anti-tigit antibodies. |
JO3663B1 (en) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | Anti-lag3 antibodies and antigen-binding fragments |
CN108271356A (en) | 2014-09-24 | 2018-07-10 | 印第安纳大学研究及科技有限公司 | Duodenin-insulin conjugate |
KR20230153495A (en) | 2014-10-01 | 2023-11-06 | 메디뮨 리미티드 | Antibodies to ticagrelor and methods of use |
MX2017005481A (en) | 2014-10-29 | 2017-10-26 | Teva Pharmaceuticals Australia Pty Ltd | Interferon a2b variants. |
WO2016069889A1 (en) | 2014-10-31 | 2016-05-06 | Resolve Therapeutics, Llc | Therapeutic nuclease-transferrin fusions and methods |
WO2016077457A1 (en) | 2014-11-11 | 2016-05-19 | Clara Foods Co. | Methods and compositions for egg white protein production |
WO2016090170A1 (en) | 2014-12-05 | 2016-06-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A potent anti-influenza a neuraminidase subtype n1 antibody |
ES2764299T3 (en) | 2014-12-09 | 2020-06-02 | Inst Nat Sante Rech Med | Human monoclonal antibodies against AXL |
US10093733B2 (en) | 2014-12-11 | 2018-10-09 | Abbvie Inc. | LRP-8 binding dual variable domain immunoglobulin proteins |
WO2016135041A1 (en) | 2015-02-26 | 2016-09-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Fusion proteins and antibodies comprising thereof for promoting apoptosis |
WO2016160976A2 (en) | 2015-03-30 | 2016-10-06 | Abbvie Inc. | Monovalent tnf binding proteins |
EP3091033A1 (en) | 2015-05-06 | 2016-11-09 | Gamamabs Pharma | Anti-human-her3 antibodies and uses thereof |
JP6867955B2 (en) | 2015-05-07 | 2021-05-12 | アジェナス インコーポレイテッド | Anti-OX40 antibody and how to use it |
ES2898023T3 (en) | 2015-05-22 | 2022-03-03 | Inst Nat Sante Rech Med | Human monoclonal antibody fragments that inhibit both the catalytic activity of Cath-D and its binding to the LRP1 receptor |
PE20180193A1 (en) | 2015-05-29 | 2018-01-26 | Abbvie Inc | ANTI-CD40 ANTIBODIES AND THEIR USES |
AU2016271323B2 (en) | 2015-06-01 | 2022-08-25 | Medimmune, Llc | Neutralizing anti-influenza binding molecules and uses thereof |
TW201710286A (en) | 2015-06-15 | 2017-03-16 | 艾伯維有限公司 | Binding proteins against VEGF, PDGF, and/or their receptors |
FR3038517B1 (en) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | USE OF MODIFIED FC FRAGMENTS IN IMMUNOTHERAPY |
US11293012B2 (en) | 2015-07-09 | 2022-04-05 | Vib Vzw | Cells producing glycoproteins having altered N- and O-glycosylation patterns and methods and use thereof |
EP3356415A1 (en) | 2015-09-29 | 2018-08-08 | Amgen Inc. | Asgr inhibitors |
KR101981943B1 (en) | 2015-10-12 | 2019-05-24 | 주식회사 에이프로젠케이아이씨 | Anti-CD43 antibodies and their use in the treatment of cancer |
JO3555B1 (en) | 2015-10-29 | 2020-07-05 | Merck Sharp & Dohme | Antibody neutralizing human respiratory syncytial virus |
WO2017106129A1 (en) | 2015-12-16 | 2017-06-22 | Merck Sharp & Dohme Corp. | Anti-lag3 antibodies and antigen-binding fragments |
RU2018128784A (en) | 2016-01-27 | 2020-02-27 | МЕДИММЬЮН, ЭлЭлСи | Methods for producing antibodies with a given glycosylation profile |
US11421028B2 (en) | 2016-02-06 | 2022-08-23 | Epimab Biotherapeutics, Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
CN108699142A (en) | 2016-02-17 | 2018-10-23 | 诺华股份有限公司 | 2 antibody of TGF β |
US10851160B2 (en) | 2016-03-22 | 2020-12-01 | Institut National De La Sante Et De La Recherche Medicale | Humanized anti-claudin-1 antibodies and uses thereof |
AU2017277534A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-EGFR antibody drug conjugates |
US20200147235A1 (en) | 2016-06-08 | 2020-05-14 | Abbvie Inc. | Anti-cd98 antibodies and antibody drug conjugates |
BR112018075653A2 (en) | 2016-06-08 | 2019-08-27 | Abbvie Inc | anti-b7-h3 antibodies and drug antibody conjugates |
AU2017277920A1 (en) | 2016-06-08 | 2019-01-03 | Abbvie Inc. | Anti-CD98 antibodies and antibody drug conjugates |
WO2017214233A1 (en) | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-egfr antibody drug conjugates |
BR112018075626A2 (en) | 2016-06-08 | 2019-03-19 | Abbvie Inc. | anti-b7-h3 antibodies and antibody drug conjugates |
JP2019521973A (en) | 2016-06-08 | 2019-08-08 | アッヴィ・インコーポレイテッド | Anti-BH7-H3 antibody and antibody drug conjugate |
MX2018015286A (en) | 2016-06-08 | 2019-08-12 | Abbvie Inc | Anti-egfr antibody drug conjugates. |
MX2018015274A (en) | 2016-06-08 | 2019-10-07 | Abbvie Inc | Anti-cd98 antibodies and antibody drug conjugates. |
CA3029627A1 (en) | 2016-07-01 | 2018-01-04 | Resolve Therapeutics, Llc | Optimized binuclease fusions and methods |
JP7241677B2 (en) | 2016-07-19 | 2023-03-17 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | Anti-CD47 combination therapy |
JP7219207B2 (en) | 2016-07-29 | 2023-02-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | Antibodies targeting tumor-associated macrophages and uses thereof |
NL2017267B1 (en) | 2016-07-29 | 2018-02-01 | Aduro Biotech Holdings Europe B V | Anti-pd-1 antibodies |
NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
EP3494143B1 (en) | 2016-08-03 | 2022-10-05 | Cipla USA, Inc. | Plazomicin antibodies and methods of use |
TWI672317B (en) | 2016-08-16 | 2019-09-21 | 英屬開曼群島商岸邁生物科技有限公司 | Monovalent asymmetric tandem fab bispecific antibodies |
KR102538827B1 (en) | 2016-08-23 | 2023-05-31 | 메디뮨 리미티드 | Anti-VEF-A Antibodies and Uses Thereof |
US10836819B2 (en) | 2016-08-23 | 2020-11-17 | Medimmune Limited | Anti-VEGF-A and anti-ANG2 antibodies and uses thereof |
US20190270821A1 (en) | 2016-09-13 | 2019-09-05 | Humanigen, Inc. | Epha3 antibodies for the treatment of pulmonary fibrosis |
JOP20190055A1 (en) | 2016-09-26 | 2019-03-24 | Merck Sharp & Dohme | Anti-cd27 antibodies |
CA3080270A1 (en) | 2016-10-25 | 2018-05-03 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Monoclonal antibodies binding to the cd160 transmembrane isoform |
EP3544628A4 (en) | 2016-11-23 | 2020-11-18 | Immunoah Therapeutics, Inc. | 4-1bb binding proteins and uses thereof |
PE20190921A1 (en) | 2016-12-07 | 2019-06-26 | Agenus Inc | ANTIBODIES AND METHODS OF THEIR USE |
EP3579872A1 (en) | 2017-02-10 | 2019-12-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of cancers associated with activation of the mapk pathway |
US11274160B2 (en) | 2017-03-02 | 2022-03-15 | INSERM (Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to Nectin-4 and uses thereof |
WO2018170332A1 (en) * | 2017-03-15 | 2018-09-20 | Nutech Ventures | Extracellular vesicles and methods of using |
US10982000B2 (en) | 2017-03-24 | 2021-04-20 | Novartis Ag | Methods for treating and/or reducing the likelihood of heart failure by administering anti-activin receptor type II (anti-ActRII) antibody |
TWI796329B (en) | 2017-04-07 | 2023-03-21 | 美商默沙東有限責任公司 | Anti-ilt4 antibodies and antigen-binding fragments |
JP7160833B2 (en) | 2017-04-13 | 2022-10-25 | サイロパ ビー.ブイ. | anti-SIRP alpha antibody |
US11932694B2 (en) | 2017-04-19 | 2024-03-19 | Bluefin Biomedicine, Inc. | Anti-VTCN1 antibodies and antibody drug conjugates |
CN111108123A (en) | 2017-05-29 | 2020-05-05 | 加马玛布斯制药公司 | Cancer-related immunosuppressive inhibitors |
UY37758A (en) | 2017-06-12 | 2019-01-31 | Novartis Ag | METHOD OF MANUFACTURING OF BIESPECTIFIC ANTIBODIES, BISPECTIFIC ANTIBODIES AND THERAPEUTIC USE OF SUCH ANTIBODIES |
GB201710838D0 (en) | 2017-07-05 | 2017-08-16 | Ucl Business Plc | Bispecific antibodies |
WO2019035916A1 (en) | 2017-08-15 | 2019-02-21 | Northwestern University | Design of protein glycosylation sites by rapid expression and characterization of n-glycosyltransferases |
BR112020003670A2 (en) | 2017-08-22 | 2020-09-01 | Sanabio, Llc | soluble interferon receptors and their uses |
MX2020002076A (en) | 2017-08-25 | 2020-03-24 | Five Prime Therapeutics Inc | B7-h4 antibodies and methods of use thereof. |
WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
WO2019148412A1 (en) | 2018-02-01 | 2019-08-08 | Merck Sharp & Dohme Corp. | Anti-pd-1/lag3 bispecific antibodies |
JP2021514379A (en) | 2018-02-21 | 2021-06-10 | ファイブ プライム セラピューティクス, インコーポレイテッド | B7-H4 antibody preparation |
MX2020008730A (en) | 2018-02-21 | 2020-12-07 | Five Prime Therapeutics Inc | B7-h4 antibody dosing regimens. |
CA3091801A1 (en) | 2018-03-02 | 2019-09-06 | Five Prime Therapeutics, Inc. | B7-h4 antibodies and methods of use thereof |
RU2020129265A (en) | 2018-03-12 | 2022-04-12 | ЗОИТИС СЕРВИСЕЗ ЭлЭлСи | ANTIBODIES AGAINST NGF AND THEIR RELATED METHODS |
US11530432B2 (en) | 2018-03-19 | 2022-12-20 | Northwestern University | Compositions and methods for rapid in vitro synthesis of bioconjugate vaccines in vitro via production and N-glycosylation of protein carriers in detoxified prokaryotic cell lysates |
US11725224B2 (en) | 2018-04-16 | 2023-08-15 | Northwestern University | Methods for co-activating in vitro non-standard amino acid (nsAA) incorporation and glycosylation in crude cell lysates |
EP3840582A4 (en) * | 2018-08-21 | 2022-08-03 | Clara Foods Co. | Modification of protein glycosylation in microorganisms |
CN112672760A (en) | 2018-09-13 | 2021-04-16 | 德克萨斯大学体系董事会 | Novel LILRB4 antibodies and uses thereof |
CN113396160A (en) | 2018-09-19 | 2021-09-14 | 国家医疗保健研究所 | Methods and pharmaceutical compositions for treating cancer resistant to immune checkpoint therapy |
EP3863722A2 (en) | 2018-10-10 | 2021-08-18 | Tilos Theapeutics, Inc. | Anti-lap antibody variants and uses thereof |
JP7448552B2 (en) | 2018-10-15 | 2024-03-12 | ファイヴ プライム セラピューティクス インク | Combination therapy for cancer |
EP3877413A1 (en) | 2018-11-06 | 2021-09-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells |
EP3894543A1 (en) | 2018-12-14 | 2021-10-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Isolated mhc-derived human peptides and uses thereof for stimulating and activating the suppressive function of cd8cd45rc low tregs |
BR112021013096A2 (en) | 2019-01-04 | 2022-04-19 | Resolve Therapeutics, Llc | TREATMENT OF SJÖGREN'S DISEASE WITH NUCLEASE FUSION PROTEINS |
WO2020148207A1 (en) | 2019-01-14 | 2020-07-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Human monoclonal antibodies binding to hla-a2 |
CN114630838A (en) | 2019-05-20 | 2022-06-14 | 法国国家健康和医学研究院 | Novel anti-CD 25 antibodies |
WO2020250159A1 (en) | 2019-06-12 | 2020-12-17 | Novartis Ag | Natriuretic peptide receptor 1 antibodies and methods of use |
KR20220034848A (en) | 2019-07-11 | 2022-03-18 | 클라라 푸드즈 컴퍼니 | Protein composition and edible products thereof |
CN114258401A (en) | 2019-07-16 | 2022-03-29 | Inserm(法国国家健康医学研究院) | Antibodies specific for CD38 and uses thereof |
US10927360B1 (en) | 2019-08-07 | 2021-02-23 | Clara Foods Co. | Compositions comprising digestive enzymes |
WO2021067526A1 (en) | 2019-10-02 | 2021-04-08 | Alexion Pharmaceuticals, Inc. | Complement inhibitors for treating drug-induced complement-mediated response |
US20220363776A1 (en) | 2019-10-04 | 2022-11-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical composition for the treatment of ovarian cancer, breast cancer or pancreatic cancer |
WO2021116119A1 (en) | 2019-12-09 | 2021-06-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity to her4 and uses thereof |
EP4093760A1 (en) | 2020-01-21 | 2022-11-30 | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd | Utilization of plant protein homologues in culture media |
KR20220137698A (en) | 2020-02-05 | 2022-10-12 | 라리마 테라퓨틱스, 인코포레이티드 | TAT peptide binding protein and uses thereof |
US20230272056A1 (en) | 2020-04-09 | 2023-08-31 | Merck Sharp & Dohme Llc | Affinity matured anti-lap antibodies and uses thereof |
AU2021265205A1 (en) | 2020-04-30 | 2023-01-05 | Academisch Ziekenhuis Groningen | Anti-CD103 antibodies |
KR20230008751A (en) | 2020-05-12 | 2023-01-16 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | Novel methods of treating cutaneous T-cell lymphoma and TFH derived lymphoma |
IL297977A (en) | 2020-05-17 | 2023-01-01 | Astrazeneca Uk Ltd | Sars-cov-2 antibodies and methods of selecting and using the same |
JP2023528535A (en) | 2020-06-25 | 2023-07-04 | メルク・シャープ・アンド・ドーム・エルエルシー | High Affinity Antibodies Targeting Tau Phosphorylated at Serine 413 |
EP4171614A1 (en) | 2020-06-29 | 2023-05-03 | Resolve Therapeutics, LLC | Treatment of sjogren's syndrome with nuclease fusion proteins |
US20230323299A1 (en) | 2020-08-03 | 2023-10-12 | Inserm (Institut National De La Santé Et De La Recherch Médicale) | Population of treg cells functionally committed to exert a regulatory activity and their use for adoptive therapy |
CA3190280A1 (en) | 2020-08-10 | 2022-02-17 | Astrazeneca Uk Limited | Sars-cov-2 antibodies for treatment and prevention of covid-19 |
WO2022106663A1 (en) | 2020-11-20 | 2022-05-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anti-cd25 antibodies |
US20240002522A1 (en) | 2020-11-20 | 2024-01-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale | Anti-cd25 antibodies |
EP4259661A1 (en) | 2020-12-14 | 2023-10-18 | Novartis AG | Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof |
JP2024503394A (en) | 2021-01-08 | 2024-01-25 | 北京韓美薬品有限公司 | Antibodies that specifically bind to 4-1BB and antigen-binding fragments thereof |
CN116635426A (en) | 2021-01-08 | 2023-08-22 | 北京韩美药品有限公司 | Antibodies and antigen binding fragments thereof that specifically bind CD47 |
WO2022148414A1 (en) | 2021-01-08 | 2022-07-14 | 北京韩美药品有限公司 | Antibody specifically binding with pd-l1 and antigen-binding fragment of antibody |
WO2022153212A1 (en) | 2021-01-13 | 2022-07-21 | Axon Neuroscience Se | Antibodies neutralizing sars-cov-2 |
AR124681A1 (en) | 2021-01-20 | 2023-04-26 | Abbvie Inc | ANTI-EGFR ANTIBODY-DRUG CONJUGATES |
EP4313317A1 (en) | 2021-03-23 | 2024-02-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the diagnosis and treatment of t cell-lymphomas |
EP4320153A1 (en) | 2021-04-09 | 2024-02-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of anaplastic large cell lymphoma |
JP2023535884A (en) | 2021-06-22 | 2023-08-22 | ノバルティス アーゲー | Bispecific antibody for use in treating hidradenitis suppurativa |
TW202342095A (en) | 2021-11-05 | 2023-11-01 | 英商阿斯特捷利康英國股份有限公司 | Composition for treatment and prevention of covid-19 |
EP4186529A1 (en) | 2021-11-25 | 2023-05-31 | Veraxa Biotech GmbH | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
WO2023094525A1 (en) | 2021-11-25 | 2023-06-01 | Veraxa Biotech Gmbh | Improved antibody-payload conjugates (apcs) prepared by site-specific conjugation utilizing genetic code expansion |
WO2023110937A1 (en) | 2021-12-14 | 2023-06-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Depletion of nk cells for the treatment of adverse post-ischemic cardiac remodeling |
WO2023144303A1 (en) | 2022-01-31 | 2023-08-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Cd38 as a biomarker and biotarget in t-cell lymphomas |
WO2023187657A1 (en) | 2022-03-30 | 2023-10-05 | Novartis Ag | Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies |
WO2023198648A1 (en) | 2022-04-11 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for the diagnosis and treatment of t-cell malignancies |
WO2023198874A1 (en) | 2022-04-15 | 2023-10-19 | Institut National de la Santé et de la Recherche Médicale | Methods for the diagnosis and treatment of t cell-lymphomas |
CN115386009B (en) * | 2022-04-26 | 2023-12-01 | 江苏靶标生物医药研究所有限公司 | Construction method and application of annexin V and angiogenesis inhibitor fusion protein |
WO2023209177A1 (en) | 2022-04-29 | 2023-11-02 | Astrazeneca Uk Limited | Sars-cov-2 antibodies and methods of using the same |
WO2023222886A1 (en) | 2022-05-20 | 2023-11-23 | Depth Charge Ltd | Antibody-cytokine fusion proteins |
WO2024003310A1 (en) | 2022-06-30 | 2024-01-04 | Institut National de la Santé et de la Recherche Médicale | Methods for the diagnosis and treatment of acute lymphoblastic leukemia |
WO2024017998A1 (en) | 2022-07-21 | 2024-01-25 | Technische Universität Dresden | M-csf for use in the prophylaxis and/or treatment of viral infections in states of immunosuppression |
EP4309666A1 (en) | 2022-07-21 | 2024-01-24 | Technische Universität Dresden | M-csf for use in the prophylaxis and/or treatment of viral infections in states of immunosuppression |
WO2024018046A1 (en) | 2022-07-22 | 2024-01-25 | Institut National de la Santé et de la Recherche Médicale | Garp as a biomarker and biotarget in t-cell malignancies |
WO2024023283A1 (en) | 2022-07-29 | 2024-02-01 | Institut National de la Santé et de la Recherche Médicale | Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas |
WO2024052503A1 (en) | 2022-09-08 | 2024-03-14 | Institut National de la Santé et de la Recherche Médicale | Antibodies having specificity to ltbp2 and uses thereof |
CN115590017B (en) * | 2022-11-04 | 2023-09-12 | 中国农业大学 | Method for improving oocyte freezing effect by reducing mitochondrial temperature |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996021038A1 (en) * | 1994-12-30 | 1996-07-11 | Alko Group Ltd. | Methods of modifying carbohydrate moieties |
WO2001014522A1 (en) * | 1999-08-19 | 2001-03-01 | Kirin Beer Kabushiki Kaisha | Novel yeast variants and process for producing glycoprotein containing mammalian type sugar chain |
Family Cites Families (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US513854A (en) * | 1894-01-30 | Clevis | ||
US4166329A (en) * | 1978-10-10 | 1979-09-04 | Herbig Charles A | Adjustable arch support for shoes |
US4414329A (en) | 1980-01-15 | 1983-11-08 | Phillips Petroleum Company | Biochemical conversions by yeast fermentation at high cell densities |
NZ199722A (en) | 1981-02-25 | 1985-12-13 | Genentech Inc | Dna transfer vector for expression of exogenous polypeptide in yeast;transformed yeast strain |
US4617274A (en) | 1981-10-29 | 1986-10-14 | Phillips Petroleum Company | Biochemical conversions by yeast fermentation at high cell densities |
US4775622A (en) | 1982-03-08 | 1988-10-04 | Genentech, Inc. | Expression, processing and secretion of heterologous protein by yeast |
KR850004274A (en) | 1983-12-13 | 1985-07-11 | 원본미기재 | Method for preparing erythropoietin |
US4655231A (en) * | 1984-01-09 | 1987-04-07 | Advanced Tobacco Products, Inc. | Snuff and preparation thereof |
US4837148A (en) | 1984-10-30 | 1989-06-06 | Phillips Petroleum Company | Autonomous replication sequences for yeast strains of the genus pichia |
US4855231A (en) | 1984-10-30 | 1989-08-08 | Phillips Petroleum Company | Regulatory region for heterologous gene expression in yeast |
US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
US4808537A (en) | 1984-10-30 | 1989-02-28 | Phillips Petroleum Company | Methanol inducible genes obtained from pichia and methods of use |
US4885242A (en) | 1984-10-30 | 1989-12-05 | Phillips Petroleum Company | Genes from pichia histidine pathway and uses thereof |
US5032516A (en) | 1985-10-25 | 1991-07-16 | Phillips Petroleum Company | Pichia pastoris alcohol oxidase II regulatory region |
US5166329A (en) | 1985-10-25 | 1992-11-24 | Phillips Petroleum Company | DNA encoding the alcohol oxidase 2 gene of yeast of the genus Pichia |
US4818700A (en) | 1985-10-25 | 1989-04-04 | Phillips Petroleum Company | Pichia pastoris argininosuccinate lyase gene and uses thereof |
US4882279A (en) | 1985-10-25 | 1989-11-21 | Phillips Petroleum Company | Site selective genomic modification of yeast of the genus pichia |
US4935349A (en) | 1986-01-17 | 1990-06-19 | Zymogenetics, Inc. | Expression of higher eucaryotic genes in aspergillus |
US5837518A (en) * | 1986-01-31 | 1998-11-17 | Genetics Institute, Inc. | Thrombolytic proteins |
US4812405A (en) | 1986-02-18 | 1989-03-14 | Phillips Petroleum Company | Double auxotrophic mutants of Pichia pastoris and methods for preparation |
US5272066A (en) | 1986-03-07 | 1993-12-21 | Massachusetts Institute Of Technology | Synthetic method for enhancing glycoprotein stability |
US4925796A (en) | 1986-03-07 | 1990-05-15 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
US4857467A (en) | 1986-07-23 | 1989-08-15 | Phillips Petroleum Company | Carbon and energy source markers for transformation of strains of the genes Pichia |
US5002876A (en) | 1986-09-22 | 1991-03-26 | Phillips Petroleum Company | Yeast production of human tumor necrosis factor |
US4683293A (en) | 1986-10-20 | 1987-07-28 | Phillips Petroleum Company | Purification of pichia produced lipophilic proteins |
US4929555A (en) | 1987-10-19 | 1990-05-29 | Phillips Petroleum Company | Pichia transformation |
US5135854A (en) | 1987-10-29 | 1992-08-04 | Zymogenetics, Inc. | Methods of regulating protein glycosylation |
US4816700A (en) * | 1987-12-16 | 1989-03-28 | Intel Corporation | Two-phase non-overlapping clock generator |
US5004688A (en) | 1988-04-15 | 1991-04-02 | Phillips Petroleum Company | Purification of hepatitis proteins |
US5047335A (en) | 1988-12-21 | 1991-09-10 | The Regents Of The University Of Calif. | Process for controlling intracellular glycosylation of proteins |
US5122465A (en) | 1989-06-12 | 1992-06-16 | Phillips Petroleum Company | Strains of pichia pastoris created by interlocus recombination |
US5032519A (en) | 1989-10-24 | 1991-07-16 | The Regents Of The Univ. Of California | Method for producing secretable glycosyltransferases and other Golgi processing enzymes |
US5324663A (en) | 1990-02-14 | 1994-06-28 | The Regents Of The University Of Michigan | Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures |
US5595900A (en) | 1990-02-14 | 1997-01-21 | The Regents Of The University Of Michigan | Methods and products for the synthesis of oligosaccharide structures on glycoproteins, glycolipids, or as free molecules, and for the isolation of cloned genetic sequences that determine these structures |
DE4028800A1 (en) | 1990-09-11 | 1992-03-12 | Behringwerke Ag | GENETIC SIALYLATION OF GLYCOPROTEINS |
CA2058820C (en) | 1991-04-25 | 2003-07-15 | Kotikanyad Sreekrishna | Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells |
US5962294A (en) | 1992-03-09 | 1999-10-05 | The Regents Of The University Of California | Compositions and methods for the identification and synthesis of sialyltransferases |
US5602003A (en) | 1992-06-29 | 1997-02-11 | University Of Georgia Research Foundation | N-acetylglucosaminyltransferase V gene |
WO1994026906A2 (en) | 1993-05-14 | 1994-11-24 | The Upjohn Company | CLONED DNA ENCODING A UDP-GALNAc:POLYPEPTIDE,N-ACETYLGALACTOS AMINYLTRANSFERASE |
US5484590A (en) | 1993-09-09 | 1996-01-16 | La Jolla Cancer Research Foundation | Expression of the developmental I antigen by a cloned human cDNA encoding a member of a β-1,6-N-acetylglucosaminyltransferase gene family |
US6300113B1 (en) * | 1995-11-21 | 2001-10-09 | New England Biolabs Inc. | Isolation and composition of novel glycosidases |
US5683899A (en) | 1994-02-03 | 1997-11-04 | University Of Hawaii | Methods and compositions for combinatorial-based discovery of new multimeric molecules |
US6069235A (en) * | 1994-02-23 | 2000-05-30 | Monsanto Company | Method for carbohydrate engineering of glycoproteins |
US6204431B1 (en) | 1994-03-09 | 2001-03-20 | Abbott Laboratories | Transgenic non-human mammals expressing heterologous glycosyltransferase DNA sequences produce oligosaccharides and glycoproteins in their milk |
HU221001B1 (en) * | 1994-03-17 | 2002-07-29 | Merck Patent Gmbh. | Anti-egfr single-chain fvs, anti-egfr antibodies |
WO1995034663A1 (en) | 1994-06-13 | 1995-12-21 | Banyu Pharmaceutical Co., Ltd. | Gene coding for glycosyltransferase and use thereof |
US5545553A (en) | 1994-09-26 | 1996-08-13 | The Rockefeller University | Glycosyltransferases for biosynthesis of oligosaccharides, and genes encoding them |
RU2149873C1 (en) * | 1994-09-27 | 2000-05-27 | Яманоути Фармасьютикал Ко., Лтд. | 1,2,3,4-tetrahydroquinoxalidinedione derivatives and pharmaceutical composition |
DE4439759C1 (en) * | 1994-11-07 | 1996-02-01 | Siemens Ag | Photodiode array for X=ray computer tomography |
US5849904A (en) | 1994-12-22 | 1998-12-15 | Boehringer Mannheim Gmbh | Isolated nucleic acid molecules which hybridize to polysialyl transferases |
JP2810635B2 (en) | 1995-04-03 | 1998-10-15 | 理化学研究所 | New sugar chain synthase |
JPH08336387A (en) | 1995-06-12 | 1996-12-24 | Green Cross Corp:The | Sugar chain-extended protein derived from pichia yeast and dna of the protein |
CA2231073A1 (en) * | 1995-09-29 | 1997-04-10 | Ossi Renkonen | Synthetic multivalent slex containing polylactosamines and methods for use |
JP3348336B2 (en) * | 1995-10-26 | 2002-11-20 | 株式会社豊田中央研究所 | Adsorption heat pump |
US5910570A (en) | 1995-11-13 | 1999-06-08 | Pharmacia & Upjohn Company | Cloned DNA encoding a UDP-GalNAc: polypeptide N-acetylgalactosaminy-ltransferase |
ATE374816T1 (en) | 1996-08-02 | 2007-10-15 | Austin Research Inst | IMPROVED NUCLEIC ACIDS ENCODING A CHIMERIC GLYCOSYL TRANSFERASE |
DE69732628T2 (en) | 1996-12-12 | 2005-12-29 | Kirin Beer K.K. | BETA 1-4 N-ACETYLGLUCOSAMINE TRANSFERASE AND THE GENE THAT CODES THEREOF |
US5945314A (en) | 1997-03-31 | 1999-08-31 | Abbott Laboratories | Process for synthesizing oligosaccharides |
US20040191256A1 (en) | 1997-06-24 | 2004-09-30 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
US7029870B1 (en) * | 1997-07-03 | 2006-04-18 | Human Genome Sciences, Inc. | Gabaa receptor epsilon subunits |
US6191271B1 (en) * | 1997-09-05 | 2001-02-20 | Glycim Oy | Synthetic divalent sLex containing polylactosamines and methods for use |
JPH11103158A (en) | 1997-09-26 | 1999-04-13 | Olympus Optical Co Ltd | Flip-chip mounting to printed wiring board and mounting structure |
US7244601B2 (en) | 1997-12-15 | 2007-07-17 | National Research Council Of Canada | Fusion proteins for use in enzymatic synthesis of oligosaccharides |
JPH11221079A (en) | 1998-02-04 | 1999-08-17 | Kyowa Hakko Kogyo Co Ltd | Transglycosidase and dna encoding the same enzyme |
WO1999040208A1 (en) | 1998-02-05 | 1999-08-12 | The General Hospital Corporation | In vivo construction of dna libraries |
WO1999054342A1 (en) | 1998-04-20 | 1999-10-28 | Pablo Umana | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
US6324663B1 (en) * | 1998-10-22 | 2001-11-27 | Vlsi Technology, Inc. | System and method to test internal PCI agents |
US6870565B1 (en) | 1998-11-24 | 2005-03-22 | Micron Technology, Inc. | Semiconductor imaging sensor array devices with dual-port digital readout |
NZ512185A (en) * | 1998-12-09 | 2004-02-27 | Dow Chemical Co | A method for manufacturing glycoproteins having human- type glycosylation in plant cells |
EP2270148A3 (en) | 1999-04-09 | 2011-06-08 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
AU7849200A (en) | 1999-10-01 | 2001-05-10 | University Of Victoria Innovation And Development Corporation | Mannosidases and methods for using same |
CA2388777A1 (en) | 1999-11-19 | 2001-05-25 | Human Genome Sciences, Inc. | 18 human secreted proteins |
AU2001241541A1 (en) | 2000-02-17 | 2001-08-27 | Millennium Predictive Medicine, Inc. | Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer |
US6410246B1 (en) * | 2000-06-23 | 2002-06-25 | Genetastix Corporation | Highly diverse library of yeast expression vectors |
US20060024304A1 (en) | 2000-06-28 | 2006-02-02 | Gerngross Tillman U | Immunoglobulins comprising predominantly a Man5GlcNAc2 glycoform |
US20060257399A1 (en) | 2000-06-28 | 2006-11-16 | Glycofi, Inc. | Immunoglobulins comprising predominantly a Man5GIcNAc2 glycoform |
US20060034828A1 (en) | 2000-06-28 | 2006-02-16 | Gerngross Tillman U | Immunoglobulins comprising predominantly a GlcNAcMAN5GLCNAC2 glycoform |
AU2001276842B2 (en) | 2000-06-28 | 2007-04-26 | Glycofi, Inc. | Methods for producing modified glycoproteins |
US7795002B2 (en) | 2000-06-28 | 2010-09-14 | Glycofi, Inc. | Production of galactosylated glycoproteins in lower eukaryotes |
US7449308B2 (en) | 2000-06-28 | 2008-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
US20060034830A1 (en) | 2000-06-28 | 2006-02-16 | Gerngross Tillman U | Immunoglobulins comprising predominantly a GalGlcNAcMan5GLcNAc2 glycoform |
US7625756B2 (en) | 2000-06-28 | 2009-12-01 | GycoFi, Inc. | Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells |
US8697394B2 (en) | 2000-06-28 | 2014-04-15 | Glycofi, Inc. | Production of modified glycoproteins having multiple antennary structures |
US7598055B2 (en) | 2000-06-28 | 2009-10-06 | Glycofi, Inc. | N-acetylglucosaminyltransferase III expression in lower eukaryotes |
US20060029604A1 (en) | 2000-06-28 | 2006-02-09 | Gerngross Tillman U | Immunoglobulins comprising predominantly a GlcNAc2Man3GlcNAc2 glycoform |
US7863020B2 (en) | 2000-06-28 | 2011-01-04 | Glycofi, Inc. | Production of sialylated N-glycans in lower eukaryotes |
AU2001277658B2 (en) | 2000-06-30 | 2006-10-19 | Research Corporation Technologies, Inc. | Protein glycosylation modification in pichia pastoris |
US7064191B2 (en) * | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
JP4655388B2 (en) | 2001-03-05 | 2011-03-23 | 富士レビオ株式会社 | Protein production method |
EP1461443A2 (en) | 2001-05-25 | 2004-09-29 | Incyte Genomics, Inc. | Carbohydrate-associated proteins |
WO2003011878A2 (en) * | 2001-08-03 | 2003-02-13 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
GB0120311D0 (en) * | 2001-08-21 | 2001-10-17 | Immunoporation Ltd | Treating cells |
CA2460621A1 (en) | 2001-09-19 | 2003-03-27 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
KR100988949B1 (en) | 2001-10-25 | 2010-10-20 | 제넨테크, 인크. | Glycoprotein compositions |
US20060024292A1 (en) | 2001-12-27 | 2006-02-02 | Gerngross Tillman U | Immunoglobulins comprising predominantly a Gal2GlcNAc2Man3GlcNAc2 glycoform |
EP2359685B1 (en) | 2001-12-27 | 2013-12-04 | GlycoFi, Inc. | Methods to engineer mammalian-type carbohydrate structures |
US20060034829A1 (en) | 2001-12-27 | 2006-02-16 | Gerngross Tillman U | Immunoglobulins comprising predominantly a MAN3GLCNAC2 glycoform |
US7332299B2 (en) | 2003-02-20 | 2008-02-19 | Glycofi, Inc. | Endomannosidases in the modification of glycoproteins in eukaryotes |
US7514253B2 (en) | 2003-05-16 | 2009-04-07 | Glycofi, Inc. | URA5 gene and methods for stable genetic integration in yeast |
US7566458B2 (en) * | 2003-06-16 | 2009-07-28 | Medimmune, Llc | Influenza hemagglutinin and neuraminidase variants |
AU2004311545B2 (en) | 2003-12-24 | 2008-11-06 | Glycofi, Inc. | Methods for eliminating mannosylphosphorylation of glycans in the production of glycoproteins |
CA2550324A1 (en) * | 2003-12-30 | 2005-07-14 | Gumlink A/S | Chewing gum comprising biodegradable polymers and having accelerated degradability |
WO2005090552A2 (en) | 2004-03-17 | 2005-09-29 | Glycofi, Inc. | Method of engineering a cytidine monophosphate-sialic acid synthetic pathway in fungi and yeast |
WO2005089047A2 (en) | 2004-03-18 | 2005-09-29 | Glycofi, Inc. | Glycosylated glucocerebrosidase expression in fungal hosts |
US7465577B2 (en) | 2004-04-29 | 2008-12-16 | Glycofi, Inc. | Methods for reducing or eliminating α-mannosidase resistant glycans for the production of glycoproteins |
US7849651B2 (en) * | 2005-05-31 | 2010-12-14 | Kubota Matsushitadenko Exterior Works, Ltd. | Wall materials bracket and insulating wall structure |
WO2007028144A2 (en) | 2005-09-02 | 2007-03-08 | Glycofi, Inc | Immunoglobulins comprising predominantly a glcnacman3glcnac2 glycoform |
WO2007061631A2 (en) * | 2005-11-15 | 2007-05-31 | Glycofi, Inc | Production of glycoproteins with reduced o-glycosylation |
US20080274162A1 (en) * | 2007-05-04 | 2008-11-06 | Jeffrey Nessa | Method, composition, and delivery mode for treatment of prostatitis and other urogenital infections using a probiotic rectal suppository |
TW201028431A (en) * | 2008-10-31 | 2010-08-01 | Lonza Ag | Novel tools for the production of glycosylated proteins in host cells |
JP2011039027A (en) * | 2009-07-14 | 2011-02-24 | Pacific Ind Co Ltd | Metallic resin cover, method for producing the same, and door handle for vehicle |
US9439972B2 (en) * | 2012-09-10 | 2016-09-13 | Ad Lunam Labs, Inc. | Antifungal serum |
-
2001
- 2001-06-27 AU AU2001276842A patent/AU2001276842B2/en not_active Ceased
- 2001-06-27 AU AU7684201A patent/AU7684201A/en active Pending
- 2001-06-27 EP EP10012383.5A patent/EP2339013B1/en not_active Expired - Lifetime
- 2001-06-27 PT PT04025648T patent/PT1522590E/en unknown
- 2001-06-27 DE DE60139720T patent/DE60139720D1/en not_active Expired - Lifetime
- 2001-06-27 CA CA002412701A patent/CA2412701A1/en not_active Abandoned
- 2001-06-27 WO PCT/US2001/020553 patent/WO2002000879A2/en active IP Right Grant
- 2001-06-27 MX MXPA03000105A patent/MXPA03000105A/en active IP Right Grant
- 2001-06-27 EP EP10011297A patent/EP2322644A1/en not_active Withdrawn
- 2001-06-27 JP JP2002506194A patent/JP2004501642A/en active Pending
- 2001-06-27 DK DK01954606T patent/DK1297172T3/en active
- 2001-06-27 DE DE60114830T patent/DE60114830T2/en not_active Revoked
- 2001-06-27 AT AT01954606T patent/ATE309385T1/en not_active IP Right Cessation
- 2001-06-27 US US09/892,591 patent/US7029872B2/en not_active Expired - Fee Related
- 2001-06-27 ES ES01954606T patent/ES2252261T3/en not_active Expired - Lifetime
- 2001-06-27 KR KR1020027017911A patent/KR100787073B1/en not_active IP Right Cessation
- 2001-06-27 DK DK04025648T patent/DK1522590T3/en active
- 2001-06-27 EP EP04025648A patent/EP1522590B1/en not_active Revoked
- 2001-06-27 EP EP09004758A patent/EP2119793A1/en not_active Withdrawn
- 2001-06-27 AT AT04025648T patent/ATE440959T1/en active
- 2001-06-27 NZ NZ523476A patent/NZ523476A/en not_active IP Right Cessation
- 2001-06-27 EP EP01954606A patent/EP1297172B1/en not_active Revoked
- 2001-06-27 ES ES04025648T patent/ES2330330T3/en not_active Expired - Lifetime
-
2005
- 2005-09-30 US US11/240,432 patent/US7326681B2/en not_active Expired - Fee Related
- 2005-10-11 US US11/249,061 patent/US7923430B2/en not_active Expired - Fee Related
- 2005-11-01 US US11/265,444 patent/US20070178551A1/en not_active Abandoned
- 2005-11-10 US US11/271,235 patent/US7629163B2/en not_active Expired - Fee Related
- 2005-11-10 US US11/271,217 patent/US20070105127A1/en not_active Abandoned
-
2007
- 2007-10-30 US US11/981,408 patent/US8211691B2/en not_active Expired - Fee Related
-
2009
- 2009-08-27 US US12/549,062 patent/US7981660B2/en not_active Expired - Fee Related
- 2009-11-25 CY CY20091101214T patent/CY1109639T1/en unknown
-
2010
- 2010-10-11 US US12/901,843 patent/US20110020870A1/en not_active Abandoned
-
2011
- 2011-03-17 JP JP2011059620A patent/JP2011167194A/en active Pending
-
2012
- 2012-05-01 US US13/461,111 patent/US20120322100A1/en not_active Abandoned
-
2013
- 2013-07-03 US US13/934,551 patent/US20130295604A1/en not_active Abandoned
-
2014
- 2014-05-07 US US14/271,475 patent/US20140234902A1/en not_active Abandoned
-
2015
- 2015-10-30 US US14/927,519 patent/US20160068880A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996021038A1 (en) * | 1994-12-30 | 1996-07-11 | Alko Group Ltd. | Methods of modifying carbohydrate moieties |
WO2001014522A1 (en) * | 1999-08-19 | 2001-03-01 | Kirin Beer Kabushiki Kaisha | Novel yeast variants and process for producing glycoprotein containing mammalian type sugar chain |
EP1211310A1 (en) * | 1999-08-19 | 2002-06-05 | Kirin Beer Kabushiki Kaisha | Novel yeast variants and process for producing glycoprotein containing mammalian type sugar chain |
Non-Patent Citations (6)
Title |
---|
CHIBA YASUNORI ET AL: "Production of human compatible high mannose-type (Man5GlcNAc2) sugar chains in Saccharomyces cerevisiae.", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, no. 41, 9 October 1998 (1998-10-09), pages 26298 - 26304, XP002202331, ISSN: 0021-9258 * |
KALSNER INGE ET AL: "Insertion into Aspergillus nidulans of functional UDP-GlcNAc: alpha-3-D-mannoside beta-1,2-N-acetylglucosaminyl-transferase I, the enzyme catalysing the first committed step from oligomannose to hybrid and complex N-glycans.", GLYCOCONJUGATE JOURNAL, vol. 12, no. 3, 1995, pages 360 - 370, XP001073956, ISSN: 0282-0080 * |
MARTINET W ET AL: "MODIFICATION OF THE PROTEIN GLYCOSYLATION PATHWAY IN THE METHYLOTROPHIC YEAST PICHIA PASTORIS", BIOTECHNOLOGY LETTERS, KEW, SURREY, GB, vol. 20, no. 12, December 1998 (1998-12-01), pages 1171 - 1177, XP001006335, ISSN: 0141-5492 * |
NAKAYAMA K-I ET AL: "OCH1 ENCODES A NOVEL MEMBRANE BOUND MANNOSYLTRANSFERASE OUTER CHAIN ELONGATION OF ASPARAGINE-LINKED OLIGOSACCHARIDES", EMBO (EUROPEAN MOLECULAR BIOLOGY ORGANIZATION) JOURNAL, vol. 11, no. 7, 1992, pages 2511 - 2519, XP002202332, ISSN: 0261-4189 * |
NIKAWA J-I ET AL: "Structural and functional conservation of human and yeast HCP1 genes which can suppress the growth defect of the Saccharomyces cerevisiae ire15 mutant", GENE, ELSEVIER BIOMEDICAL PRESS. AMSTERDAM, NL, vol. 171, no. 1, 24 May 1996 (1996-05-24), pages 107 - 111, XP004042777, ISSN: 0378-1119 * |
WIGGINS CHRISTINE A R ET AL: "Activity of the yeast MNN1 alpha-1,3-mannosyltransferase requires a motif conserved in many other families of glycosyltransferases.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 95, no. 14, 7 July 1998 (1998-07-07), July 7, 1998, pages 7945 - 7950, XP002202333, ISSN: 0027-8424 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8877462B2 (en) | 2000-06-28 | 2014-11-04 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
US8883483B2 (en) | 2000-06-28 | 2014-11-11 | Glycofi, Inc. | Combinatorial DNA library for producing modified N-glycans in lower eukaryotes |
US9574218B2 (en) | 2001-01-19 | 2017-02-21 | Phyton Holdings, Llc | Method of co-expressing galactosyltransferase and a glycoprotein in a transgenic plant cell and sialylating the glycoprotein for production of glycoprotein having human-type sugar chain |
US8986949B2 (en) | 2003-02-20 | 2015-03-24 | Glycofi, Inc. | Endomannosidases in the modification of glycoproteins in eukaryotes |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002000879A3 (en) | Methods for producing modified glycoproteins | |
WO2007087420A3 (en) | Production of proteins carrying oligomannose or human-like glycans in yeast and methods of use thereof | |
WO2004074458A3 (en) | N-acetylglucosaminyltransferase iii expression in lower eukaryotes | |
WO1998006835A3 (en) | Modifying insect cell gylcosylation pathways with baculovirus expression vectors | |
EP2196540A3 (en) | Combinatorial DNA library for producing modified N-Glycans in lower eukaryotes | |
WO1999067398A3 (en) | Overexpression of phytase genes in yeast systems | |
DE69837604D1 (en) | Expression heterologer proteine | |
CA2063592A1 (en) | Process for preparing a protein by a fungus transformed by multicopy integration of an expression vector | |
Lee et al. | An episomal expression vector for screening mutant gene libraries in Pichia pastoris | |
MX2008000200A (en) | Polynucleotides encoding isoprenoid modifying enzymes and methods of use thereof. | |
CA2490268A1 (en) | Protein glycosylation modification in pichia pastoris | |
WO1999060102A3 (en) | Improved in vivo production of cephalosporins | |
MX9606476A (en) | The cytoplasmic inhibition of gene expression. | |
WO2006096050A3 (en) | Glycoengineering in mushrooms | |
US20120029174A1 (en) | Methods for producing substantially homogeneous hybrid or complex n-glycans in methylotrophic yeasts | |
WO2021195464A3 (en) | Modified mammalian cells having reduced host cell proteins | |
CN204788079U (en) | Net adds muscle formula shell structure | |
Lee et al. | Expression of Escherichia coli AppA2 phytase in four yeast systems | |
CA2230975A1 (en) | Wheat aleurone promoter | |
Yoo et al. | Screening and selection of production strains: secretory protein expression and analysis in Hansenula polymorpha | |
WO2021231488A3 (en) | D-allulose 3-epimerases for bioconversion of d-fructose to d-allulose | |
WO2004011670A3 (en) | Methods and compositions for nad(p)(h) oxidases | |
Yoshida et al. | Filamentous fungus Aspergillus oryzae has two types of α-1, 2-mannosidases, one of which is a microsomal enzyme that removes a single mannose residue from Man9GlcNAc2 | |
WO2000039307A3 (en) | Recombinant bacterial strains for the production of natural nucleosides and modified analogues thereof | |
WO2023130078A3 (en) | Genetically modified mycelium for producing psychotropic alkaloids |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2412701 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001276842 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2002 506194 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027017911 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 523476 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/000105 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001954606 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001954606 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027017911 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 523476 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 523476 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001954606 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001276842 Country of ref document: AU |